Halozyme Therapeutics, Inc. (HALO)
108.64
+0.47
(+0.43%)
USD |
NASDAQ |
Aug 24, 16:00
108.64
0.00 (0.00%)
After-Hours: 19:20
Halozyme Therapeutics Price to Book Value : 86.31 for Aug. 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 85.94 |
| August 20, 2026 | 84.31 |
| August 19, 2026 | 85.50 |
| August 18, 2026 | 83.33 |
| August 17, 2026 | 81.83 |
| August 14, 2026 | 78.38 |
| August 13, 2026 | 79.98 |
| August 12, 2026 | 80.87 |
| August 11, 2026 | 81.53 |
| August 10, 2026 | 81.53 |
| August 07, 2026 | 81.93 |
| August 06, 2026 | 68.13 |
| August 05, 2026 | 66.41 |
| August 04, 2026 | 66.12 |
| August 03, 2026 | 65.36 |
| July 31, 2026 | 65.58 |
| July 30, 2026 | 66.18 |
| July 29, 2026 | 66.16 |
| July 28, 2026 | 66.30 |
| July 27, 2026 | 64.73 |
| July 24, 2026 | 65.09 |
| July 23, 2026 | 64.23 |
| July 22, 2026 | 61.83 |
| July 21, 2026 | 62.45 |
| July 20, 2026 | 61.25 |
| Date | Value |
|---|---|
| July 17, 2026 | 61.82 |
| July 16, 2026 | 61.60 |
| July 15, 2026 | 60.24 |
| July 14, 2026 | 59.63 |
| July 13, 2026 | 60.47 |
| July 10, 2026 | 60.54 |
| July 09, 2026 | 62.46 |
| July 08, 2026 | 63.85 |
| July 07, 2026 | 64.81 |
| July 06, 2026 | 64.18 |
| July 02, 2026 | 63.12 |
| July 01, 2026 | 61.18 |
| June 30, 2026 | 62.18 |
| June 29, 2026 | 41.65 |
| June 26, 2026 | 40.45 |
| June 25, 2026 | 39.20 |
| June 24, 2026 | 38.39 |
| June 23, 2026 | 37.57 |
| June 22, 2026 | 37.23 |
| June 18, 2026 | 36.99 |
| June 17, 2026 | 37.00 |
| June 16, 2026 | 37.58 |
| June 15, 2026 | 38.47 |
| June 12, 2026 | 37.50 |
| June 11, 2026 | 38.17 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Incyte Corp. | 4.054 |
| Neurocrine Biosciences, Inc. | 4.210 |
| AVITA Medical, Inc. | -- |
| Agenus, Inc. | -- |
| Amgen, Inc. | 20.53 |
Price to Book Value Related Metrics
| PE Ratio | 32.46 |
| PS Ratio | 7.903 |
| Price to Free Cash Flow | 16.31 |
| Price | 108.64 |
| Earnings Yield | 3.08% |
| Market Cap | 12.39B |
| Operating PE Ratio | 13.92 |
| Normalized PE Ratio | 19.95 |